Swedish Orphan Biovitrum Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Guido Oelkers

Chief executive officer

kr48.9m

Total compensation

CEO salary percentage	25.1%
CEO tenure	7yrs
CEO ownership	0.1%
Management average tenure	5.3yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Guido Oelkers's remuneration changed compared to Swedish Orphan Biovitrum's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	kr2b
Dec 31 2023	kr49m	kr12m	kr2b
Sep 30 2023	n/a	n/a	kr3b
Jun 30 2023	n/a	n/a	kr3b
Mar 31 2023	n/a	n/a	kr3b
Dec 31 2022	kr47m	kr11m	kr3b
Sep 30 2022	n/a	n/a	kr2b
Jun 30 2022	n/a	n/a	kr3b
Mar 31 2022	n/a	n/a	kr3b
Dec 31 2021	kr42m	kr10m	kr3b
Sep 30 2021	n/a	n/a	kr3b
Jun 30 2021	n/a	n/a	kr3b
Mar 31 2021	n/a	n/a	kr3b
Dec 31 2020	kr33m	kr10m	kr3b
Sep 30 2020	n/a	n/a	kr3b
Jun 30 2020	n/a	n/a	kr3b
Mar 31 2020	n/a	n/a	kr4b
Dec 31 2019	kr33m	kr10m	kr3b
Sep 30 2019	n/a	n/a	kr3b
Jun 30 2019	n/a	n/a	kr3b
Mar 31 2019	n/a	n/a	kr3b
Dec 31 2018	kr26m	kr9m	kr2b
Sep 30 2018	n/a	n/a	kr2b
Jun 30 2018	n/a	n/a	kr2b
Mar 31 2018	n/a	n/a	kr1b
Dec 31 2017	kr16m	kr5m	kr1b

Compensation vs Market: Guido's total compensation ($USD4.52M) is above average for companies of similar size in the UK market ($USD3.33M).

Compensation vs Earnings: Guido's compensation has been consistent with company performance over the past year.

CEO

Guido Oelkers (58 yo)

7yrs

Tenure

kr48,883,000

Compensation

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Guido Oelkers	CEO & President	7yrs	kr48.88m	0.11% SEK 104.4m
Henrik Stenqvist	Chief Financial Officer	5.8yrs	no data	0.015% SEK 13.8m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.3yrs	no data	0.0079% SEK 7.5m
Daniel Rankin	Head of Strategy & Corporate Development	2.3yrs	no data	0.0058% SEK 5.5m
Lena Bjurner	Head of Human Resources	1.3yrs	no data	no data
Armin Reininger	Senior Scientific & Medical Advisor	7.3yrs	no data	0.0047% SEK 4.5m
Norbert Oppitz	Head of International	6.6yrs	no data	0.010% SEK 9.7m
Sofiane Fahmy	Head of Europe	5.3yrs	no data	0.0078% SEK 7.4m
Duane Barnes	Head of North America	3.3yrs	no data	no data
Mahmood Ladha	Head of Strategic Transformation Operations	no data	no data	0.0018% SEK 1.8m
Christine Wesstrom	Head of Technical Operations	2.2yrs	no data	0.0030% SEK 2.9m
Lydia Abad-Franch	Senior VP	1.3yrs	no data	no data

5.3yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 0MTD's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Hans Wigzell	Chairman of Scientific Advisory Board	23.3yrs	kr158.00k	no data
Helena Saxon	Director	13.1yrs	kr828.00k	0.0059% SEK 5.6m
Anders Ullman	Director	less than a year	kr463.00k	0.00088% SEK 837.4k
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	no data	no data
Ralf Pettersson	Member of Scientific Advisory Board	no data	no data	no data
Stefan Del Prato	Member of Scientific Advisory Board	no data	no data	no data
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	no data	no data
Annette Clancy	Independent Chairman	10yrs	kr770.00k	0.0010% SEK 951.6k
Staffan Schuberg	Independent Director	4yrs	kr827.00k	0.0019% SEK 1.8m
Filippa Stenberg	Director	3yrs	kr673.00k	0.00015% SEK 142.7k
Katy Mazibuko	Employee Representative Director	1.3yrs	no data	no data
Christophe Bourdon	Independent Director	less than a year	kr433.00k	no data

3.5yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 0MTD's board of directors are considered experienced (3.5 years average tenure).

Swedish Orphan Biovitrum Management

Management criteria checks 3/4

Key information

Recent management updates

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Independent Director recently bought kr439k worth of stock

Recent updates

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

New minor risk - Insider selling

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings released: EPS: kr0.30 (vs kr1.52 in 3Q 2022)

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings released: EPS: kr0.75 (vs kr0.87 in 2Q 2022)

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021)

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021)

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released: EPS: kr1.52 (vs kr1.60 in 3Q 2021)

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa

Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings released: EPS: kr0.87 (vs kr0.91 in 2Q 2021)

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi

Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member

First quarter 2022 earnings released: EPS: kr1.84 (vs kr2.36 in 1Q 2021)

Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study

Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH)

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022

Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others.

Investor sentiment deteriorated over the past week

Head of Technical Operations recently bought kr1.3m worth of stock

Third quarter 2021 earnings released: EPS kr1.60 (vs kr0.94 in 3Q 2020)

Swedish Orphan Biovitrum AB (publ) Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia

Nature Medicine Publishes Phase 3 Anakinra Study Results in Patients with Covid-19 Pneumonia

Investor sentiment improved over the past week

Orphan Biovitrum Jumps After Bloomberg Report of Potential Takeover

Second quarter 2021 earnings released: EPS kr0.91 (vs kr0.96 in 2Q 2020)

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

CEO & President recently bought kr8.2m worth of stock

Swedish Orphan Biovitrum AB (publ) Announces Early Use of Anakinra Reduces Risk of Mortality for Patients with Covid-19 Pneumonia, Reduces ICU Admission and Increases Likelihood of Full Recovery

CEO & President recently bought kr4.2m worth of stock